Sign In
Buy WVE
$5.76
+0.0700 (+1.23%)
At Close: Jun 03, 2026
FDA reversals leave investors worrying about the fates of other experimental drugs
11:33am, Friday, 06'th Mar 2026
The FDA in the past year has denied or discouraged applications of at least eight new drugs, according to RTW Investments. The agency initially refused to review Moderna's flu shot before reversing co
Data from the RestorAATion-2 clinical trial of WVE-006 (GalNAc-RNA editing), including new data from the 400 mg multidose cohort and 600 mg single dose cohort, will now be presented at the ATS confere
Wave Life Sciences Ltd. (WVE) Q4 2025 Earnings Call Transcript
03:57pm, Thursday, 26'th Feb 2026
Wave Life Sciences Ltd. (WVE) Q4 2025 Earnings Call Transcript
Wave Life Sciences (WVE) Reports Q4 Loss, Tops Revenue Estimates
01:21pm, Thursday, 26'th Feb 2026
Wave Life Sciences (WVE) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to earnings of $0.17 per share a year ago.
Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
07:30am, Thursday, 26'th Feb 2026
On track for INLIGHT clinical data update in 1Q 2026; fat loss similar to GLP-1 observed at three months and expected to continue over time and with higher doses of WVE-007 (INHBE GalNAc-siRNA), while
Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
08:30am, Monday, 23'rd Feb 2026
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
08:30am, Thursday, 19'th Feb 2026
AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotechnology mergers and acquisitions (M&As) are increasingly shaped by a clear strategic evolution. Pharmaceutical com
Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026
08:30am, Thursday, 19'th Feb 2026
CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform
Wave Life Sciences Reclaims Rare Disease Drug From GSK, Targets Faster FDA Path
02:16pm, Monday, 02'nd Feb 2026
On Monday, Wave Life Sciences Ltd. (NASDAQ: WVE) said it regained full rights to WVE-006 from GSK Plc (NYSE: GSK).
WVE-006 is a first-in-class RNA editing therapeutic candidate designed to correct the root cause of disease for the 200,000 individuals in the U.S. and Europe living with AATD; no currently approved t
WAVE Life Sciences Ltd. $WVE Shares Sold by Emerald Advisers LLC
04:53am, Thursday, 22'nd Jan 2026
Emerald Advisers LLC lowered its position in shares of WAVE Life Sciences Ltd. (NASDAQ: WVE) by 8.0% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 2,99
MoneyShow's Best Investment Ideas For 2026: Part 9
12:40pm, Wednesday, 21'st Jan 2026
MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, an
This Director Sold 42,000 Shares of Wave Life Sciences for $630,000. What Investors Should Know About This Biotech Company.
08:18am, Wednesday, 14'th Jan 2026
Adrian Rawcliffe disposed of 42,000 shares for a total transaction value of ~$630,000 on Dec. 8, 2025. This transaction was derivative-based, involving the exercise and immediate sale of options; all
Wave Life Sciences Ltd. (WVE) Presents at 44th Annual J.P.
08:26pm, Tuesday, 13'th Jan 2026
Wave Life Sciences Ltd. (WVE) Presents at 44th Annual J.P.
Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity with higher BMI and comorbidities in 1H 2026, and initiate new trials of WVE-
